Essential Planning LLC. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Essential Planning LLC. acquired a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 413,088 shares of the biotechnology company's stock, valued at approximately $4,437,000. Essential Planning LLC. owned about 0.49% of Anavex Life Sciences as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Nwam LLC acquired a new stake in shares of Anavex Life Sciences in the 3rd quarter valued at about $5,172,000. Barclays PLC boosted its position in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after purchasing an additional 64,101 shares during the period. Geode Capital Management LLC boosted its position in shares of Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company's stock valued at $10,699,000 after purchasing an additional 51,946 shares during the period. Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences in the 4th quarter valued at about $291,000. Finally, Gladstone Institutional Advisory LLC acquired a new stake in shares of Anavex Life Sciences in the 4th quarter valued at about $279,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AVXL. HC Wainwright reissued a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, February 18th. D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Remove Ads

Anavex Life Sciences Trading Down 0.9 %

Anavex Life Sciences stock opened at $8.90 on Thursday. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44. The stock has a 50 day moving average of $9.48 and a two-hundred day moving average of $7.99. The stock has a market capitalization of $757.07 million, a price-to-earnings ratio of -16.18 and a beta of 0.94.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03. Equities analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.